67976-82-3

Basic information

• Product Name: 3-Cyclohexene-1-carboxylic acid, (1S)-, compd. with (αR)-α-methylbenzenemethanamine (1:1)
• Synonyms: 3-Cyclohexene-1-carboxylic acid, (1S)-, compd. with (αR)-α-methylbenzenemethanamine (1:1)
• CAS NO: 67976-82-3
• Molecular Formula: C15H21NO2
• Molecular Weight: 247.337
• Mol File: 67976-82-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-Cyclohexene-1-carboxylic acid, (1S)-, compd. with (αR)-α-methylbenzenemethanamine (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Cyclohexene-1-carboxylic acid, (1S)-, compd. with (αR)-α-methylbenzenemethanamine (1:1)(67976-82-3)
• EPA Substance Registry System: 3-Cyclohexene-1-carboxylic acid, (1S)-, compd. with (αR)-α-methylbenzenemethanamine (1:1)(67976-82-3)

Safety Data

• Hazardous Substances Data: 67976-82-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
3-Cyclohexene-1-carboxylic acid, (1S)-, compd. with (αR)-α-methylbenzenemethanamine (1:1) is used as a pharmaceutical intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Its unique structure and properties may contribute to the development of new therapeutic agents with improved efficacy and selectivity.
Used in Materials Science:
In the field of materials science, 3-Cyclohexene-1-carboxylic acid, (1S)-, compd. with (αR)-α-methylbenzenemethanamine (1:1) may be utilized in the development of novel materials with specific properties, such as chiral catalysts, chiral ligands, or chiral stationary phases for chromatographic separations.
Used in Organic Chemistry:
3-Cyclohexene-1-carboxylic acid, (1S)-, compd. with (αR)-α-methylbenzenemethanamine (1:1) can be employed as a reagent or catalyst in various organic synthesis processes, potentially leading to the development of new synthetic routes and methodologies.
Further research and experimentation may be necessary to fully understand and utilize the properties of this chemical complex in these and other potential applications.

Upstream product

• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 139893-81-5 (1S,4S,5S)-4-bromo-6-oxabicyclo<3.2.1>octan-7-one 
• 6493-77-2 (R)-(+)-methyl 3-cyclohexene-1-carboxylate 
• 5709-98-8 (R)-cyclohex-3-enecarboxylic acid 
• 6493-77-2 methyl cyclohex-3-ene-1-carboxylate 
• 4771-80-6 1,2,5,6-tetrahydrobenzoic acid 
• 1228540-49-5 Ethyl (R)-3-cyclohexene-1-carboxylate 
• 15111-56-5 ethyl-3-cyclohexene-1-carboxylate 
• 1352834-09-3 cyclohex-3-ene-1-carboxylic acid (R)-(+)-1-phenylethanamine salt 

Downstream Products

• 5708-19-0 (1S)-3-cyclohexenecarboxylic acid 
• 1350734-43-8 {(1S,2S,4S)-4-[(tert-butoxycarbonyl)-amino]-2-hydroxy-cyclohexyl}-benzene-carbothioate 
• 1350734-44-9 {(1R,2R,5S)-5-[(tert-butoxycarbonyl)amino]-2-hydroxycyclohexyl}benzene-carbothioate 
• 1255529-39-5 (S)-3-cyclohexene-1-carboxylic acid benzyl ester 
• 1255529-40-8 (1R,3S,6S)-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid benzyl ester 
• 1255529-42-0 (1S,3R,4R)-4-[(tert-butoxycarbonyl)amino]-3-hydroxycyclohexanecarboxylic acid benzyl ester 
• 615569-03-4 (1S,3R,4R)-4-[(tert-butoxycarbonyl)amino]-3-hydroxycyclohexanecarboxylic acid methyl ester 
• 1255529-45-3 (1S,3R,4R)-3-azido-4-[(tert-butoxycarbonyl)amino]cyclohexanecarboxylic acid methyl ester 
• 1255529-44-2 (1S,3S,4R)-3-azido-4-[(tert-butoxycarbonyl)amino]cyclohexanecarboxylic acid methyl ester 
• 1255529-48-6 (1S,3S,4R)-3-{[(benzyloxy)carbonyl]amino}-4-[(tert-butoxycarbonyl)amino]cyclohexanecarboxylic acid methyl ester 
• 1255529-43-1 (1S,3R,4R)-4-[(tert-butoxycarbonyl)amino]-3-hydroxycyclohexanecarboxylic acid methyl ester 
• 1352833-87-4 tert-Butyl [(1S,3S,4S)-3-hydroxy-4-mercapto-cyclohexyl]-carbamate 
• 1255529-36-2 ethyl (1R,3R,4R)-4-(((benzyloxy)carbonyl)amino)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 480449-84-1 ethyl (1S,3R,4S)-4-amino-3-[(tert-butoxycarbonyl)amino]-cyclohexanecarboxylate 

Relevant articles and documents

Preparation method of edoxaban

The invention relates to a new preparation route and a new method for a p-toluenesulfonic acid edoxaban hydrate and intermediates thereof. The new method comprises the steps that a high-reactivity compound 109A4x is prepared; a compound 109C6x is prepared by using a new synthesizing method; new compounds 109E8-01, 109E9x and 109T7-01 are prepared; the p-toluenesulfonic acid edoxaban hydrate is prepared by using the intermediates. By using the new method and the new route, the reaction step of copious cooling is omitted, and dangerous elemental sulfur, high-risk n-butyllithium and high-risk azides are prevented from being used. In a word, by means of the method, the p-toluenesulfonic acid edoxaban hydrate and the key intermediates thereof are more easily and safely prepared at a lower coston an industrialization scale.

METHOD FOR PRODUCING (1S,4S,5S)-4-BROMO-6-OXABICYCLO[3.2.1]OCTAN-7-ONE

It is an object of the present invention to provide a method for efficiently producing (1S,4S,5S)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one (1), which is important as an intermediate compound for the production of an FXa-inhibiting compound. A method for producing (1S,4S,5S)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one (1), which comprises treating an (R)-α-phenylethylamine salt of (S)-3-cyclohexene-1-carboxylic acid with 1,3-dibromo-5,5-dimethylhydantoin or N-bromosuccinimide in a solvent.

Process for the preparation of pleuromutilins

A process for the preparation of a compound of formula in the form of a single stereoisomer, comprising deprotecting the amine group in an N-protected amino-hydroxy-cyclohexylsulfanyl-acetyl-mutilin of formula wherein R is an amine protecting group in the form of a single stereoisomer, and isolating a compound of formula I in the form of a single stereoisomer obtained from the reaction mixture; compounds obtainable by such processes, e.g. a compound of formula I in a crystalline form, or salts of a compound of formula I in crystalline form, and processes for the preparation of intermediates for the production of a compound of formula I.